Related to disease, we found that PAK6 is hyperactivated in G2019S and idiopathic PD (iPD) post‐mortem brains compared to healthy controls, highlighting PAK6 as a novel pharmacological target in PD. This evidence concerns the gene PAK6 and Parkinson disease.